Hikal Limited (HIKAL) — Financial Results(2 announcements)

Investor Takeaways

Overall Tone: Neutral

Key Financial Highlights

What Changed

Hikal Limited reported consolidated revenue of ₹519 crore and PAT of ₹14 crore for Q4 FY26. The PAT figure reflects improvement from ₹55 crore (pre-exceptional) to ₹14 crore (reported) after accounting for an exceptional ₹47 crore impairment charge. EBITDA reached ₹105 crore with a 20.3% margin, indicating margin expansion. Crop Protection revenue grew 45% quarter-on-quarter, contributing to sequential improvements in both margins and volume growth. The company highlighted recovery across Pharmaceuticals and Crop Protection segments. Forward guidance points to commercialization of new products in Specialty Chemicals and Personal Care expected from FY27 onwards. The Q4 results show a turnaround pattern with improved operational efficiency and margin recovery compared to previous quarters.

Peer Comparison

Hikal trades at a lower P/E multiple compared to Sun Pharmaceutical and Divi's Laboratories, suggesting potential relative valuation advantage. The company's market capitalization is significantly lower than its peers, reflecting its smaller scale. Peer companies show higher ROE and ROCE metrics, indicating stronger returns on equity and capital. Hikal's financial ratios do not currently match the efficiency levels observed in the larger pharmaceutical peers.

Risks & Concerns

Quarterly Trend

Investor Takeaways

Overall Tone: Neutral

Key Financial Highlights

What Changed

Hikal Limited reported consolidated revenue of ₹1,713 crores for FY26, reflecting an 8% year-on-year decline, with EBITDA margin compressing to 12.9% from 17.7% in FY25. The company achieved a quarterly EBITDA of ₹105 crores in Q4FY26, driven by a 20.3% margin, while PAT stood at ₹14 crores for the quarter. Pharmaceutical revenue grew 60% sequentially in H2 FY26 to ₹629 crores, supported by CDMO expansion and new product demand. Crop Protection revenue rose 45% QoQ to ₹228 crores, with volume recovery offsetting pricing pressures. The company emphasized strategic investments in high-potency chemistry capabilities and diversification into Specialty Chemicals and Personal Care, with new product commercialization expected from FY27. Balance sheet remains disciplined, though exceptional items including a Rs. 38 crore impairment and labor code adjustments impacted profitability.

Peer Comparison

Hikal’s P/E ratio of 33.35 is lower than Sun Pharmaceutical’s 41.28 and significantly lower than Divi's Laboratories’ 72.41 and Torrent Pharmaceuticals’ 80.06, indicating relatively lower valuation expectations compared to peers.

Risks & Concerns

Quarterly Trend

The quarterly trend shows a peak in profitability in Q4FY24 with ₹33.97 crore profit and 18.37% OPM, followed by a sustained decline in both profit and margin through FY25. The full-year FY26 revenue decline and margin compression to 12.9% indicate a challenging operating environment, though quarterly EBITDA improved to ₹105 crores with 20.3% margin in Q4FY26, suggesting recent operational stabilization.

Hikal is transitioning from remediation to sustainable growth through strategic investments in high-value segments, though near-term profitability faces pressure from exceptional items and margin compression.

About Hikal Limited (HIKAL)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

View full HIKAL stock details →